June 1, 2018 05:57 PM EDTUpdated June 4, 02:54 PM
R&D

Blue­bird, Cel­gene add a promis­ing chap­ter to their suc­cess sto­ry with BC­MA-tar­get­ing CAR-T — and turn it around with in­vestors

John Carroll

Editor & Founder

CHICA­GO — Right now at Cel­gene $CELG and blue­bird $BLUE, it’s all about the Kar­M­Ma — and they’re look­ing to bur­nish theirs at AS­CO. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times